Abstract
Albumin from plasma fractionation is generally considered to be a safe and effective product. Nevertheless, a growing number of factors makes recombinant albumin manufacture increasingly attractive, i.e. the perceived risk of viral contamination in serum albumin, likelihood of reduced availability of recovered plasma in the future, and price. As a result of production technology evaluation, the expression of human albumin in the milk of transgenic cows has been identified as the most promising approach. A major challenge for this project is the fact that the production of pharmaceutical proteins on the scale of many tons, essentially free of any impurities at the price level of a commodity has not been achieved in recombinant biotechnology so far. In collaboration with Genzyme Transgenics Corp. (Framingham) project activities were initiated in February 1997.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literature
Peters, 1996, All about Albumin, Academic Press Ltd., ISBN0-12552110-3
Jones, 1996, J. Americ. Blood Res. Assoc. 4:108–110
Wilmutetal et al., 1996, Nature 380:64–66
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Eichner, W., Sommermeyer, K. (2002). Large Scale Production of Rh-Albumin Expressed in the Milk of Transgenic Cattle — An Economic and Technical Challenge. In: Ikura, K., Nagao, M., Masuda, S., Sasaki, R. (eds) Animal Cell Technology: Challenges for the 21st Century. Springer, Dordrecht. https://doi.org/10.1007/0-306-46869-7_36
Download citation
DOI: https://doi.org/10.1007/0-306-46869-7_36
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-5805-3
Online ISBN: 978-0-306-46869-8
eBook Packages: Springer Book Archive